Longacting exenatide in diabetes: DURATION-3.
Misra
Anoop
A
Fortis Hospital, New Delhi 110 070, India. anoopmisra@metabolicresearchindia.com
Joshi
Shashank
S
D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D010455:Peptides / Q000008:administration & dosage*; D014688:Venoms / Q000008:administration & dosage*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D014688:Venoms; D000069036:Insulin Glargine; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide